- Data Safety Monitoring Board recommends continuation of the trial with no safety concerns
- Preliminary data from 6 month dosing is indicative of positive drug effect at dose tested
PR Newswire
MELBOURNE, Australia, Sept. 17, 2019
PR Newswire
MELBOURNE, Australia, Sept. 17, 2019
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey